10 results match your criteria: "WHO Collaborating Centre for Sexually Transmitted Infections and Antimicrobial Resistance[Affiliation]"
Emergence of an extensively drug-resistant Neisseria gonorrhoeae clone.
Lancet Infect Dis
September 2024
WHO Collaborating Centre for Sexually Transmitted Infections and Antimicrobial Resistance, New South Wales Health Pathology, Microbiology, The Prince of Wales Hospital, Randwick, NSW 2031, Australia; Faculty of Medicine, The University of New South Wales, NSW 2052, Australia. Electronic address:
The novel 2024 WHO Neisseria gonorrhoeae reference strains for global quality assurance of laboratory investigations and superseded WHO N. gonorrhoeae reference strains-phenotypic, genetic and reference genome characterization.
J Antimicrob Chemother
August 2024
WHO Collaborating Centre for Sexually Transmitted Infections and Antimicrobial Resistance, New South Wales Health Pathology, Microbiology, Randwick, NSW, Australia.
Article Synopsis
- MDR and XDR strains of Neisseria gonorrhoeae are significant global health threats, prompting the importance of monitoring antimicrobial resistance (AMR) through WHO programs like GASP and EGASP.
- The 2024 WHO gonococcal reference strains include 15 strains characterized phenotypically and genomically, consisting of both new strains and updates to earlier ones.
- These reference strains showcase various resistance profiles and genetic features vital for quality assurance in laboratories and are crucial for diagnosing gonorrhea and predicting AMR trends.
High prevalence of ceftriaxone-resistant and XDR in several cities of Cambodia, 2022-23: WHO Enhanced Gonococcal Antimicrobial Surveillance Programme (EGASP).
JAC Antimicrob Resist
April 2024
Department of the Global HIV, Hepatitis and STI Programmes, WHO, Geneva, Switzerland.
Article Synopsis
- Antimicrobial resistance (AMR) is a significant global health issue, particularly for gonorrhoea treatment, with ceftriaxone being the last effective option, yet resistance cases from Asia have been reported.
- A study conducted by the WHO in Cambodia analyzed 437 male patients from January 2022 to June 2023, revealing resistance rates of 15.4% for ceftriaxone and high levels for other antibiotics, including 6.2% of samples being extensively drug-resistant (XDR).
- The findings emphasize the urgent need for improved AMR surveillance, updates to treatment protocols, mandatory follow-up testing, and the development of new antibiotics to effectively combat gonorrhoea.
The Enhanced Gonococcal Surveillance Programme, Cambodia.
Lancet Infect Dis
September 2023
WHO Collaborating Centre for Sexually Transmitted Infections and Antimicrobial Resistance, New South Wales Health Pathology, Microbiology, The Prince of Wales Hospital Randwick, NSW, Australia. Electronic address:
WHO global antimicrobial resistance surveillance for Neisseria gonorrhoeae 2017-18: a retrospective observational study.
Lancet Microbe
November 2021
Department of the Global HIV, Hepatitis and STI programmes, WHO, Geneva, Switzerland.
Background: Gonorrhoea and antimicrobial resistance (AMR) in Neisseria gonorrhoeae are major health concerns globally. Increased global surveillance of gonococcal AMR is essential. We aimed to describe the 2017-18 data from WHO's global gonococcal AMR surveillance, and to discuss priorities essential for the effective management and control of gonorrhoea.
View Article and Find Full Text PDFDeveloping target product profiles for Neisseria gonorrhoeae diagnostics in the context of antimicrobial resistance: An expert consensus.
PLoS One
October 2020
World Health Organization (WHO), Geneva, Switzerland.
Background: There is a need for a rapid diagnostic point of care test to detect Neisseria gonorrhoeae (NG) infection to prevent incorrect, lack or excess of treatment resulting from current syndromic management in low-resource settings. An assay to identify NG antimicrobial resistance (AMR) is also highly desirable to facilitate antibiotic stewardship. Here we describe the development of two target product profiles (TPPs): one for a test for etiological diagnosis of NG and Chlamydia trachomatis (CT) (TPP1) and one for the detection of NG AMR/susceptibility (TPP2).
View Article and Find Full Text PDFLessons learnt from ceftriaxone-resistant gonorrhoea in the UK and Australia.
Lancet Infect Dis
March 2020
WHO Collaborating Centre for Sexually Transmitted Infections and Antimicrobial Resistance, New South Wales Health Pathology, Department of Microbiology, The Prince of Wales Hospital, Randwick, NSW, Australia; Faculty of Medicine, School of Medical Sciences, University of New South Wales, NSW, Australia.
Emergence and spread of ciprofloxacin-resistant Neisseria gonorrhoeae in New South Wales, Australia: lessons from history.
J Antimicrob Chemother
August 2019
WHO Collaborating Centre for Sexually Transmitted Infections and Antimicrobial Resistance, NSWHP Microbiology, Prince of Wales Hospital, Sydney, New South Wales 2031, Australia.
Objectives: Our aim was to investigate the emergence and spread of ciprofloxacin resistance in clinical Neisseria gonorrhoeae isolates in New South Wales, Australia, from the first reported case in 1991 until ciprofloxacin resistance was sustained at or above the WHO threshold for treatment change of 5% (1999), to inform future strategies for controlling gonococcal antimicrobial resistance.
Methods: The index isolate and all subsequent clinical isolates of ciprofloxacin-resistant N. gonorrhoeae in New South Wales from 1991 to 1999 were genotyped using a previously described method on the Agena MassARRAY iPLEX platform.
Systematic review and survey of Neisseria gonorrhoeae ceftriaxone and azithromycin susceptibility data in the Asia Pacific, 2011 to 2016.
PLoS One
December 2019
WHO Collaborating Centre for Sexually Transmitted Infections and Antimicrobial Resistance, New South Wales Health Pathology, Microbiology, Prince of Wales Hospital, Randwick, New South Wales, Australia.
Background: Antimicrobial resistance in Neisseria gonorrhoeae is a global concern, with the ongoing emergence of ceftriaxone and azithromycin resistance threatening current treatment paradigms. To monitor the emergence of antimicrobial resistance in N. gonorrhoeae, the World Health Organization (WHO) Gonococcal Antimicrobial Surveillance Programme (GASP) has operated in the Western Pacific and South East Asian regions since 1992.
View Article and Find Full Text PDFTreatment for pharyngeal gonorrhoea under threat.
Lancet Infect Dis
November 2018
Pathology Queensland, Brisbane, QLD, Australia; Faculty of Medicine, University of Queensland, Brisbane, QLD, Australia.